Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macroflux microprojection array patch technology: a new and efficient approach for intracutaneous immunization.

James A Matriano1, Michel Cormier, Juanita Johnson

  • 1Biological Sciences, ALZA Corporation, Mountain View, California 94043, USA. james.matriano@alza.com

Pharmaceutical Research
|February 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human Growth Hormone Delivery with a Microneedle Transdermal System: Preclinical Formulation, Stability, Delivery and PK of Therapeutically Relevant Doses.

Pharmaceutics·2014
Same author

Erythropoietin-coated ZP-microneedle transdermal system: preclinical formulation, stability, and delivery.

Pharmaceutical research·2012
Same author

A minimally invasive jet injector for intravitreal and subconjunctival injection.

Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye·2012
Same author

Parathyroid hormone (1-34)-coated microneedle patch system: clinical pharmacokinetics and pharmacodynamics for treatment of osteoporosis.

Pharmaceutical research·2010
Same author

Demonstrated solid-state stability of parathyroid hormone PTH(1-34) coated on a novel transdermal microprojection delivery system.

Pharmaceutical research·2010
Same author

Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women.

The Journal of clinical endocrinology and metabolism·2009
Same journal

Leveraging Carnitine-functionalized Lipid Nanocarrier based Targeted Delivery of A1874 PROTAC for Glioblastoma.

Pharmaceutical research·2026
Same journal

Impact of Febrile State on Vancomycin Clearance in Pediatric Patients: Insights From Population Pharmacokinetic Modeling.

Pharmaceutical research·2026
Same journal

Sustained Intra-Articular Delivery of Triple Therapeutics Using a Phase-Transition Phospholipid-Based Gel for Effective Treatment of Gouty Arthritis.

Pharmaceutical research·2026
Same journal

Spray Dried Lysozyme Microspheres: Morphological Evolution and Enzymatic Activity Retention.

Pharmaceutical research·2026
Same journal

Colloidal Stability of Amorphous Nanoparticles in Solution: Impact of Stabilizer.

Pharmaceutical research·2026
Same journal

Impact of Mixing Approach and Bubble Formation on In Situ Forming Implant Properties.

Pharmaceutical research·2026
See all related articles

The Macroflux skin patch offers a needle-free way to deliver protein antigens intracutaneously. This novel technology shows promise for enhancing vaccine efficacy and convenience.

Area of Science:

  • Biotechnology
  • Immunology
  • Dermatology

Background:

  • Protein antigen delivery is crucial for vaccine development.
  • Intracutaneous delivery targets skin immune cells for enhanced responses.
  • Novel delivery systems are needed to improve vaccine efficacy and patient compliance.

Purpose of the Study:

  • To evaluate the Macroflux microprojection array patch for intracutaneous delivery of protein antigens.
  • To assess the delivery characteristics and immunogenicity of ovalbumin (OVA) using the Macroflux system.
  • To compare Macroflux delivery with traditional parenteral vaccination methods.

Main Methods:

  • Macroflux microprojection array patches were coated with ovalbumin (OVA).
  • Microprojection penetration depth and OVA delivery were measured in a hairless guinea pig model.

Related Experiment Videos

  • Immune responses, including antibody titers, were compared between Macroflux and conventional delivery routes.

    • Main Results:

    • Macroflux microprojections achieved an average skin penetration depth of 100 microm.
    • Rapid delivery of OVA (up to 20 microg in 5 s) was achieved with the Macroflux system.
    • Macroflux delivery at low doses elicited immune responses up to 50-fold greater than subcutaneous or intramuscular administration.

    Conclusions:

    • Macroflux technology enables rapid, reproducible, and needle-free intracutaneous antigen administration.
    • The system allows controlled antigen delivery by adjusting formulation, wear time, and patch size.
    • This patch technology holds potential for broad applications in therapeutic vaccines, improving efficacy and user convenience.